KR900018070A - N-(아릴옥시알킬)헤테로아릴피페리딘 및 -헤테로아릴피페라진, 이의 제조방법 및 약제로서의 이의 용도 - Google Patents

N-(아릴옥시알킬)헤테로아릴피페리딘 및 -헤테로아릴피페라진, 이의 제조방법 및 약제로서의 이의 용도 Download PDF

Info

Publication number
KR900018070A
KR900018070A KR1019900007102A KR900007102A KR900018070A KR 900018070 A KR900018070 A KR 900018070A KR 1019900007102 A KR1019900007102 A KR 1019900007102A KR 900007102 A KR900007102 A KR 900007102A KR 900018070 A KR900018070 A KR 900018070A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
hydrogen
alkoxy
Prior art date
Application number
KR1019900007102A
Other languages
English (en)
Other versions
KR0157308B1 (ko
Inventor
토마스 스트루프쎄프스키 죠셉
클리블랜드 헤슬리 그로버
치앙 율린
제이. 보르도 케네스
Original Assignee
원본미기재
훼스트-러셀 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 훼스트-러셀 파마슈티칼즈 인코포레이티드 filed Critical 원본미기재
Publication of KR900018070A publication Critical patent/KR900018070A/ko
Application granted granted Critical
Publication of KR0157308B1 publication Critical patent/KR0157308B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음

Description

N-(아릴옥시알킬)헤테로아릴피페리딘 및 -헤테로아릴피페라진, 이의 제조방법 및 약제로서의 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (19)

  1. 일반식(Ⅰ)의 화합물 또는 약제학적으로 허용되는 이의 산 부가염.
  3. 상기식에서, X는 -O-, -S-, -NH- 또는이고, P는 1 또는 2이며, Y는 P가 1인 경우 수소, C1-C6-알킬, -OH, C1, F, Br, I, C1-C6-알콕시, -CF3, -NO2또는 -NH2이고, P가 2이고 X가 -O-인 경우, 저급 알콕시이며, R2는 저급 알킬, 아릴저급 알킬, 아릴, 사이클로알킬, 아로일, 알카노일 및 페닐설포닐 그룹으로 이루어진 그룹 중에서 선택되고, Z는또는이며, n은 2,3,4 또는 5이고, R은 수소, 알킬, C1-C6-알콕시, 하이드록실, 카복실, CI, F, Br, I, 아미노, C1-C6모노 또는 디알킬 아미노, -NO2, 저급알킬티오, -OCF3, 시아노, 아실아미노, -CF3, 트리플루오로아세틸, 아미노 카보닐,알킬,O-알킬,아릴,헤테로 아릴 또는알킬 [여기서, 알킬은 저급 알킬이고, 아릴은 페닐 또는 일반식의 그룹(여기서, R1은 수소, 저급 알킬, C1-C6-알콕시, 하이드록시, CI, F, Br, I, C1-C6알킬 아미노, -NO2, -CN, -CF3또는 -OCF3이다)이며, 헤테로아릴은 일반식의 그룹(여기서, Q는 -O-, -S-,또는 -CH=N 이다)이고, R3은 수소, 저급 알킬 또는 아실이다]이며, m은 1.2 또는 3이다.
  4. 제1항에 있어서, X는 -O-, -S- 또는 -NH인 화합물.
  5. 제2항에 있어서, n은 2,3 또느 ㄴ4이고 Y는 수소이거나 6위치에서 염소 또는 불소이며 p는 1인 화합물.
  6. 제3항에 있어서, R은 수소, 알킬, C1-C6-알콕시, C1-C6-알킬티오, 할로겐, C1-C6-알킬아미노,알킬,페닐 또는 -CH(OR3)-C1-C6-알킬이고 m은 2 또는 3인 화합물.
  7. 제3항에 있어서, n은 3 또는 4이고, m은 2이며 R은 -OCH3또는인 화합물.
  8. 제1항에 있어서, 1-[4-[3-[4-(1H-인다졸-3-일)-1-피페라지닐]프로폭시]-3-메톡시페닐]에탄온 또는 약제학적으로 허용되는 이의 산 부가염.
  9. 제1항에 있어서, 1-[4-[3-[4-(1,2-베느이속사졸-3-일)-1-피페라디닐]프로폭시]-3-메톡시페닐]에탄온 또는 약제학적으로 허용되는 이의 산 부가염.
  10. 제1항에 있어서, 1-[4-[3-[4-(6-플루오로-1,2-벤즈이속사졸-3-일)-1-피페라지닐]프로폭시]-3-메톡시페닐]에탈온 또는 약제학적으로 허용되는 이의 산 부가염.
  11. 제1항에있어서,1-[4-[4-[4-(1,2-벤즈이속사졸-3-일)-1-피페라지닐]부록시]-3-메톡시페닐]에탈온 또는 약제학적으로 허용되는 이의 산 부가염.
  12. 제1항에 있어서, 1-[4-[4-[4-(6-플루오로-1,2-벤즈이속사졸-3-일)-1-피페라지닐]부록시]-3-메톡시페닐]에탈온 또는 약제학적으로 허용되는 이의 산 부가염.
  13. 활성성분으로 제1항에서 청구한 화합물과 이에 적합한 담체를 포함하는 약제학적 조성물.
  14. 정신병 치료 활성 및/또는 진통 활성이 있는 약제를 제조하기 위한, 제1항에서 청구한 화합물의 용도.
  15. a)일반식(Ⅱ)의 화합물을 알킬화 조건하에 일반식(Ⅲ)의 화합물과 반응시키고, b)임의로 R이-C6-알킬인 일반식(Ⅰ)의 화합물을 환원시켜 R이 CH2(OH)-C1-C6-알킬인 일반식(Ⅰ)의 화합물을 수득하고, c)임의로 R이 -CH(OR3)-C1-C6-알킬이고, R3은 수소인 일반식(Ⅰ)의 화합물을 알카노산 무수물과 반응시켜 R이 C1-C6-알카노일인 일반식(Ⅰ)의 화합물을 수득하고, d)임의로 R이 하이드록시인 일반식(Ⅰ)의 화합물을 우선 강염기와 반응시키고, 이어서 일반식 Hal-C1-C6알킬의 화합물(여기서, Hal은 염소 또는 브롬이다)과 반응시켜 R이 C1-C6-알콕시인 일반식(Ⅰ)의 화합물을 수득하고, e)임의로 X가 N-R2이고, R2는 수소인 일반식(Ⅰ)의 화합물을 C1-C6-알카노일 또는 아로일 할라이드와 반응시켜 X가 NR2이고 R2는 C1-C6-알카노일 또는 아로일인 일반식(Ⅰ)의 화합물을 수득함을 특징으로 하여, 제1항에서 청구한 화합물을 제조하는 방법.
  17. 상기식에서, X,Y,X,R,m,n 및 p는 제1항에서 정의한 바와 같고, Hal은 염소 또는 브롬이다.
  18. 제13항에 있어서, 단계a)으 반응을 불활성 용매 중에서 50℃ 내지 용매의 환류온도에서 산 수용체의 존재하에 수행하는 방법.
  19. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900007102A 1989-05-19 1990-05-18 N-(아릴옥시알킬)헤테로아릴피페리딘 및 -헤테로아릴피페라진, 이의 제조방법 및 이를 함유하는 약제학적 조성물 KR0157308B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US35441189A 1989-05-19 1989-05-19
US354,411 1989-05-19
US354411 1989-05-19
US45679089A 1989-12-29 1989-12-29
US456,790 1989-12-29
US456790 1989-12-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008308A Division KR930009238B1 (ko) 1990-05-24 1991-05-23 콘버젼스 보정장치

Publications (2)

Publication Number Publication Date
KR900018070A true KR900018070A (ko) 1990-12-20
KR0157308B1 KR0157308B1 (ko) 1998-11-16

Family

ID=26998389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007102A KR0157308B1 (ko) 1989-05-19 1990-05-18 N-(아릴옥시알킬)헤테로아릴피페리딘 및 -헤테로아릴피페라진, 이의 제조방법 및 이를 함유하는 약제학적 조성물

Country Status (24)

Country Link
EP (1) EP0402644B1 (ko)
JP (1) JPH0662580B2 (ko)
KR (1) KR0157308B1 (ko)
CN (2) CN1086387C (ko)
AT (1) ATE126512T1 (ko)
AU (1) AU640653B2 (ko)
CA (1) CA2017193C (ko)
CZ (1) CZ282385B6 (ko)
DD (1) DD300433A5 (ko)
DE (1) DE69021645T2 (ko)
DK (1) DK0402644T3 (ko)
ES (1) ES2076253T3 (ko)
FI (2) FI104072B1 (ko)
GR (1) GR3017447T3 (ko)
HK (2) HK1006710A1 (ko)
HU (2) HU218200B (ko)
IE (1) IE68431B1 (ko)
IL (1) IL94425A (ko)
NO (1) NO177301C (ko)
NZ (1) NZ233710A (ko)
PL (1) PL163965B1 (ko)
PT (1) PT94084B (ko)
RU (3) RU2062776C1 (ko)
SK (1) SK242590A3 (ko)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561128A (en) * 1989-05-19 1996-10-01 Hoechst-Roussel Pharmaceuticals, Inc. N-[(4-(heteroaryl)-1-piperidinyl)alkyl]-10,11-dihydro-5H-dibenz[B,F]azepines and related compounds and their therapeutic utility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
US5177088A (en) * 1991-04-17 1993-01-05 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 3-(pyridinylamino)-indoles
TW241263B (ko) * 1991-08-22 1995-02-21 Hoechst Roussel Pharma
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5378714A (en) * 1991-11-27 1995-01-03 Novo Nordisk A/S Antipsychotic piperidine derivatives
WO1993010742A2 (en) * 1991-11-27 1993-06-10 Novo Nordisk A/S Chemical compounds, their preparation and use
WO1993013068A1 (en) * 1991-12-25 1993-07-08 Zeria Pharmaceutical Co., Ltd. Tricyclic compound and medicine containing the same
AU678186B2 (en) * 1992-10-23 1997-05-22 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
CA2146018A1 (en) * 1992-10-23 1994-05-11 Paul David Leeson Dopamine receptor subtype ligands
DK60793D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
DK60593D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
GB9318691D0 (en) * 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
WO1995007893A1 (en) * 1993-09-15 1995-03-23 Merck Sharp & Dohme Limited Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
ES2101646B1 (es) * 1995-04-12 1998-04-01 Ferrer Int Nuevo compuesto derivado del cromeno.
US5668148A (en) * 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
DE69611783T2 (de) * 1995-06-06 2001-09-20 Aventis Pharma Inc Benzisoxazol- und indazol- derivate als antipsychotika
CA2241845C (en) * 1996-01-05 2002-10-01 Hoechst Marion Roussel, Inc. 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity
US5880121A (en) * 1996-01-05 1999-03-09 Hoechst Marion Roussel Inc. 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
ES2144355B1 (es) * 1997-12-30 2001-01-01 Ferrer Int Compuestos derivados del cromeno.
WO2001017993A1 (en) * 1999-09-09 2001-03-15 EGIS Gyógyszergyár Rt. Alkylpiperidi nylbenzo [d] isoxazole derivatives having psychotropic activity, pharmaceutical compositions containing the same, and a process for the preparation of the active ingredient
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
EP2305656B1 (en) * 2001-08-31 2012-10-24 Novartis AG Optical isomers of an iloperidone metabolite
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
MXPA05002007A (es) * 2002-09-17 2005-04-28 Warner Lambert Co Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia.
CA2505397A1 (en) * 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス，エルエルシー 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
CN101824030B (zh) * 2009-03-04 2014-06-18 北京德众万全药物技术开发有限公司 一种伊潘立酮的制备方法
EP3309151A1 (en) 2009-06-25 2018-04-18 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011032404A1 (zh) * 2009-09-19 2011-03-24 浙江华海药业股份有限公司 伊潘立酮的一种制备方法及结晶方法
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
US20120220776A1 (en) * 2009-11-19 2012-08-30 Symed Labs Limited Process for the preparation of iloperidone using a novel intermediate
WO2011154860A1 (en) * 2010-06-08 2011-12-15 Alembic Pharmaceuticals Limited An improved process for preparing iloperidone
CN102311430A (zh) * 2010-06-29 2012-01-11 大道隆达（北京）医药科技发展有限公司 伊潘立酮的新晶态及其制备方法
ITMI20101294A1 (it) * 2010-07-14 2012-01-15 Dipharma Francis Srl Procedimento per la preparazione di iloperidone
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012123963A2 (en) 2011-02-24 2012-09-20 Megafine Pharma (P) Ltd. A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
WO2012153341A1 (en) 2011-05-12 2012-11-15 Arch Pharmalabs Limited A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
WO2012164516A1 (en) 2011-06-03 2012-12-06 Lupin Limited Process for the preparation of iloperidone
ITMI20120511A1 (it) * 2012-03-29 2013-09-30 Procos Spa Processo one-pot per la sintesi di iloperidone
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015095783A1 (en) 2013-12-20 2015-06-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355037A (en) * 1981-11-12 1982-10-19 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidyl)-1,2-benzisoxales
US4458076A (en) * 1983-05-31 1984-07-03 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidinyl)-1,2-benzisothiazoles
HU198036B (en) * 1983-08-22 1989-07-28 Hoechst Roussel Pharma Process for production of derivatives of 3-piperidil-/1h/-indasole and medical preparatives containing them
US4590196A (en) * 1984-08-23 1986-05-20 Bristol-Myers Company Analgesic 1,2-benzisothiazol-3-ylpiperazine derivatives

Also Published As

Publication number Publication date
HK1006710A1 (en) 1999-03-12
CZ282385B6 (cs) 1997-07-16
JPH0662580B2 (ja) 1994-08-17
PL163965B1 (pl) 1994-05-31
NO902214D0 (no) 1990-05-18
PT94084B (pt) 1996-12-31
RU2147583C1 (ru) 2000-04-20
CZ242590A3 (en) 1997-03-12
FI104072B (fi) 1999-11-15
HU211853A9 (en) 1995-12-28
SK279474B6 (sk) 1998-11-04
HU903090D0 (en) 1990-09-28
GR3017447T3 (en) 1995-12-31
NO177301C (no) 1995-08-23
NO902214L (no) 1990-11-20
DE69021645T2 (de) 1996-02-22
AU5577090A (en) 1990-11-22
CA2017193A1 (en) 1990-11-19
IL94425A0 (en) 1991-03-10
EP0402644B1 (en) 1995-08-16
DD300433A5 (de) 1992-06-11
RU2239434C2 (ru) 2004-11-10
DK0402644T3 (da) 1996-01-02
FI104072B1 (fi) 1999-11-15
KR0157308B1 (ko) 1998-11-16
DE69021645D1 (de) 1995-09-21
NO177301B (no) 1995-05-15
SK242590A3 (en) 1998-11-04
RU2062776C1 (ru) 1996-06-27
IL94425A (en) 1994-02-27
CA2017193C (en) 2000-06-27
AU640653B2 (en) 1993-09-02
HU218200B (hu) 2000-06-28
HK1038316A1 (en) 2002-03-15
FI19991869A (fi) 1999-09-02
IE68431B1 (en) 1996-06-12
ES2076253T3 (es) 1995-11-01
IE901809L (en) 1990-11-19
CN1048037A (zh) 1990-12-26
CN1086387C (zh) 2002-06-19
CN1305812A (zh) 2001-08-01
HUT58720A (en) 1992-03-30
NZ233710A (en) 1992-05-26
FI902449A0 (fi) 1990-05-17
EP0402644A1 (en) 1990-12-19
PL285247A1 (en) 1991-02-11
PT94084A (pt) 1991-01-08
JPH0363263A (ja) 1991-03-19
CN1223348C (zh) 2005-10-19
ATE126512T1 (de) 1995-09-15

Similar Documents

Publication Publication Date Title
KR900018070A (ko) N-(아릴옥시알킬)헤테로아릴피페리딘 및 -헤테로아릴피페라진, 이의 제조방법 및 약제로서의 이의 용도
GB2063249A (en) 4-Phenylphthalazine derivatives
KR960017658A (ko) 알파₁-아드레날린수용체 길항물질로서의 [3-(4-페닐피페라진-1-일)프로필-아미노, 티오 및 옥시］-피리딘, 피리미딘 및 벤젠 유도체
KR860008976A (ko) 2-(4-벤조일-1- 피페리딜)-1- 페닐알칸올 유도체
US4933355A (en) Thiazole derivatives, their preparation and their use in the treatment of diabetes complications
HU211625A9 (en) Novel 2-saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US4107317A (en) Chroman derivatives
SE7710873L (sv) Nya 1h-pyrazolo(3,4-b)pyridiner
KR900003156A (ko) 진통제 화합물, 그의 제조방법 및 그를 함유하는 약학 조성물
KR920016452A (ko) N-(아릴옥시알킬)헤테로아릴-8-아자비시클로[3.2.1]옥탄, 중간체, 이의 제조방법 및 약제로서 이의 용도
HUT68879A (en) 2-saccharinylmethyl-aryl-carboxylate derivatives and pharmaceutical compositions containing them
US3236855A (en) Certain n-phenyl(thiazole-hydroxamidine) compounds and their preparation
US3337576A (en) Arylthioalkyltetrazoles
KR840007870A (ko) 히드록실아민 유도체의 제조방법
US3898230A (en) Sydnone imine compounds
KR840001166A (ko) 스피로티아졸리딘일 피페라진 유도체 제조방법
KR920006346A (ko) 3-(1h-인다졸-3-일)-4-피리딘아민, 이의 제조방법, 이의 제조를 위한 중간체 및 약제로서의 이의 용도
KR840007420A (ko) 치환된 카복시-티아졸로[3,2-α] 피리미딘 유도체의 제조방법
JPH0437073B2 (ko)
KR790001502B1 (ko) 벤조-2, 4-티아제핀의 제조방법
KR810001981B1 (ko) 2, 5-디히드로-1, 2-티아지노[5, 6-b] 인돌-3-카복사미드-1, 1-디옥사이드의 제조방법
KR960004338A (ko) 신규한 7-아미노옥시피롤리딘 퀴놀린 카르복실산 유도체 및 그의 제조방법
KR810001978B1 (ko) 2, 5-디히드로-1, 2티아지노 [5, 6-b]인돌-3-카복사미드-1, 1-디옥사이드의제조 방법
KR850000757B1 (ko) 티아졸린 유도체의 제조방법
KR960703126A (ko) 5-ht1a_1a 리간드로서의 아베오-에르골린 유도체(abeo-ergoline derivatives as 5ht1a ligands)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120628

Year of fee payment: 15

EXPY Expiration of term